Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

n the Committed Equity Financing Facility with Kingsbridge, and our plans regarding collaborations and other partnering activities. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the SEC on November 6, 2008, as well as other filings by the company with the SEC.

(Tables Follow)

    Micromet, Inc.
    Condensed Consolidated Balance Sheets
    (In thousands, except par value)

                                               December 31,   December 31,
  
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: ... elected Rene-Pierre Azria as a Director and ... oversight on strategic and financial transactions. Mr. Azria will ... Compensation Committee and the Corporate Governance and Nomination Committee. ... have a long-time interest in Life Sciences and in ...
(Date:4/21/2015)... Genomics, a leading provider of cloud-based genomic medicine technology, today ... of Marketing. Mr. Forsythe is the latest to join the ... operations over the last two quarters. ... a tremendous addition to the Tute Genomics team," stated ... vast experience commercializing software technology in a highly complex and ...
(Date:4/21/2015)... -- Novogen Limited (ASX:NRT; NASDAQ: NVGN ) ("Company" or ... has entered into definitive agreements today to issue ... attaching 6-month option and half of one attaching ... institutional investors in the United States ... gross proceeds of approximately AU$15,500,000 ("Placement"). The closing ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that it will ... open on Tuesday, April 28, 2015. United ... 28, 2015, at 9:00 a.m. Eastern Time.  The teleconference ... 1-970-315-0533.  A rebroadcast of the teleconference will be available ...
Breaking Biology Technology:Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6
... JERSEY CITY, New Jersey, August 12, Rosetta Genomics ... first quarter financial results on August 19, 2008, ... a conference call with a,simultaneous webcast to discuss ... 19., To access the live conference call, ...
... Calif., Aug. 12 ChromaDex,Corporation, (OTC Bulletin Board: ... research, today announced financial results for the,second quarter ... accordance with,U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex ... $0.03 per share for the,three months ended June ...
... -- 3SBio Inc.,(Nasdaq: SSRX ), a leading ... marketing biopharmaceutical,products, today announced its unaudited financial results ... Second Quarter 2008 Financial Highlights: -- ... quarter 2007 to RMB59.6 ...
Cached Biology Technology:Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 33SBio Inc. Announces Second Quarter 2008 Results 23SBio Inc. Announces Second Quarter 2008 Results 33SBio Inc. Announces Second Quarter 2008 Results 43SBio Inc. Announces Second Quarter 2008 Results 53SBio Inc. Announces Second Quarter 2008 Results 63SBio Inc. Announces Second Quarter 2008 Results 73SBio Inc. Announces Second Quarter 2008 Results 83SBio Inc. Announces Second Quarter 2008 Results 93SBio Inc. Announces Second Quarter 2008 Results 103SBio Inc. Announces Second Quarter 2008 Results 113SBio Inc. Announces Second Quarter 2008 Results 123SBio Inc. Announces Second Quarter 2008 Results 133SBio Inc. Announces Second Quarter 2008 Results 143SBio Inc. Announces Second Quarter 2008 Results 15
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... notorious for their thick skin and well-armored bodies. So it comes ... touch is one of the most acute in the animal kingdom. ... of small, pigmented domes that dot their skin all over their ... jaws. A new study, published in the Nov. 8 issue ...
... 7, 2012 Listed below are the selected highlights for ... journal, GENETICS . The November issue is available ... , Vol. 192, November 2012, Copyright 2012. Please ... in these articles. ISSUE HIGHLIGHTS , An ...
... Every week in his clinic at the University of Michigan, ... dying or shrinking due to disease or injury. ... other effects that nerve-destroying conditions cause and wishes he ... regenerate their nerves. Then he heads to his research lab ...
Cached Biology News:Despite their thick skins, alligators and crocodiles are surprisingly touchy 2Despite their thick skins, alligators and crocodiles are surprisingly touchy 3Genetics Society of America's GENETICS journal highlights for November 2012 2Genetics Society of America's GENETICS journal highlights for November 2012 3Genetics Society of America's GENETICS journal highlights for November 2012 4Stem cells + nanofibers = Promising nerve research 2Stem cells + nanofibers = Promising nerve research 3
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Biology Products: